免疫毒素(TCS-Hepama-1)及其与阿霉素(ADM)合用对荷人肝癌裸鼠的治疗作用

Antitumor Effect of TCS-Hepama-1 Immunotoxin and Its Combined Use with ADM on Human Hepatoma Bearing Nude Mice

荷瘤裸鼠分治疗组4组，T1为TCS-Hepama-1＋ADM组，T2为TCS-Hepama-1高剂量组，T3为TCS-Hepama-1低剂量组，T4为ADM组；对照组也分4组，C1为生理盐水组，C2为TCS组，C3为TCS＋Hepama-1组及C4为TCS-NMIgG组。实验表明，治疗组裸鼠的精神状态、食欲、体重等一般状况均好于对照组。治疗组抑瘤效果明显，尤以T1组为最佳，抑瘤率达92％，说明免疫毒素与阿霉素合用有协同作用。治疗组裸鼠血清AFP值改变明显低于对照组（P＜0．01）。显微镜检查治疗组裸鼠的肿瘤主要由坏死组织组成，而对照组裸鼠的肿瘤组织以团块型为主，坏死少，肿瘤向周围浸润性生长，并可经血路转移至肺。治疗组裸鼠主要器官经肉眼及显微镜观察未见受损表现。说明免疫毒素TCS-Hepama-1具有明显的抑瘤作用，与抗癌药合用，具有协同作用，既可增强疗效又可减少药量避免毒副反应，为TCS-Hepama-1的临床应用提供了可靠的依据。

Forty nude mice bearing hepatoma were divided into two groups,treatment group and control group, and each was further divided into four subgroups. Each subgroup of 5 mice was injected i. p. six times every other day at doses of TCS-Hepama-1 20μg+ADM 20μg for T1 group, TCS-Hepama-1 40μg for T2 group, TCS-Hepama-1 30μg for T3 group,ADM 30μg for T4 group,normal saline 0. 2ml for C1 group, TCS 30μg for C2 group, TCS 30μg+Hepama-1 30μg for C3 group and TCS-NM1gG 30μg for C4 group. General condition in terms of spirit,appetite and weight of the mice in the treatment groups was obviously better than that in the control groups. Tumor inhibiting effect in the treatment groups was significant and the tumor inhibition rate was 92% in T1 group indicating that there was synergistic action between TCS-Hepama-1 and ADM. AFP values in mice of the treatment groups were much lower than those of the control groups (P<0. 05).Microscopically necrosis of tumor was more apparent in mice of the treatment groups than in the control groups. Vital organs of the mice in the treatment groups showed no damage. It is suggested that immunotoxin TCS-Hepama-1 possesses marked tumor inhibiting effect and has synergistic action combined with other antitumor drugs.